Alliance Global Partners analyst Scott Henry downgraded Vivos Therapeutics (VVOS) to Neutral from Buy with a price target of $2.25, down from $5.50. The firm views the company’s visibility as low pending signs of execution for its new business model, which it says is unlikely before the second half of 2025. Vivos has limited financial resources to manage this uncertainty, the analyst tells investors in a research note. Alliance points out the company’s Q1 results trailed forecasts as the business model shifts from dentists to sleep specialists.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VVOS:
- Vivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial Challenges
- Vivos Therapeutics Shifts Strategy Amid Financial Results
- Vivos Therapeutics announces agreement to acquire operating assets of SCN
- Vivos Therapeutics’ Earnings Call Highlights Growth and Expansion
- Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global Partners